サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1555504

口腔内崩壊錠市場：薬物タイプ別、適応症別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Orally Disintegrating Tablet Market, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 390 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
口腔内崩壊錠市場：薬物タイプ別、適応症別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年08月20日
発行: AnalystView Market Insights
ページ情報: 英文 390 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

口腔内崩壊錠の市場規模は2023年に131億2,312万米ドルとなり、2024年から2032年にかけてCAGR 8.1％で拡大

口腔内崩壊錠市場- 市場力学

バイオアベイラビリティの向上と利便性の向上が市場需要を促進する見込み

ODTは特定の薬剤のバイオアベイラビリティを向上させ、より効果的にすることができます。これは、迅速な作用発現を必要とする薬剤にとって特に有益です。ODTは、小児医療や老人医療だけでなく、メンタルヘルス、アレルギー、疼痛管理など、さまざまな治療分野で使用されるようになってきています。このような幅広い用途が市場の成長を後押ししています。従来の錠剤よりもODTの方が使いやすく、水を必要としないため、患者はODTを好むことが多いです。患者のコンプライアンスが向上すれば治療成績も向上し、ひいては需要も高まる。

さらに、ODTは従来の錠剤やカプセルを飲み込むことが困難な患者にとって実用的なソリューションとなります。これには、小児、高齢者、特定の病状を持つ患者が含まれます。水を必要としない投与のしやすさは、患者のコンプライアンス向上に貢献しています。錠剤製剤技術の革新により、ODTの味、安定性、有効性が改善されました。製造プロセスの進歩により、より効果的で患者にやさしいODTが可能になった。

口腔内崩壊錠市場-主要インサイト

リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約8.1%のCAGRで毎年成長すると推定されます。

薬剤タイプ別セグメンテーションによると、アレルギー疾患の増加により、抗アレルギー薬セグメントは2023年に最大の市場シェアを示すと予測されました。

適応症別では、心血管治療におけるODTのニーズの高さから、心血管疾患分野が2023年の主要適応症でした。

流通チャネル別では、病院でのODTの需要が高いことから、病院薬局が2023年の流通チャネルのトップでした。

地域別では、慢性疾患の有病率の増加により、北米が2023年に収益でリードしました。

口腔内崩壊錠市場-セグメンテーション分析：

口腔内崩壊錠の世界市場は、薬物タイプ、適応症、流通チャネル、地域に基づいてセグメント化されます。

薬剤タイプ別では、抗精神病薬、抗てんかん薬、抗高血圧薬、抗不安薬、抗アレルギー薬、プロトンポンプ阻害薬、その他の7つに分類されます。市場を独占しているのは抗アレルギー薬です。アレルギー疾患の有病率の高さが抗アレルギー錠剤の需要を伸ばしています。

市場は適応症別に神経疾患、心血管疾患、消化器疾患、アレルギー疾患、その他の5つに分類されます。心血管疾患分野が市場を独占しています。ODTはあらゆる心血管疾患の治療に広く使用されており、これが同分野の成長を後押ししています。

市場は流通チャネルによって、病院薬局、オンライン薬局、その他の3つに分類されます。病院薬局分野は市場を独占しており、予測期間中も高い優位性を維持すると予想されます。オンライン薬局セグメントは予測期間中に最も速い速度で成長すると予測されます。

口腔内崩壊錠市場：地域別インサイト

地域的には、北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカの各地域に広がっています。北米はODTの世界市場で大きなシェアを占めており、その主な理由は高度なヘルスケアインフラと慢性疾患の高い有病率にあります。アジア太平洋地域は、ヘルスケアへのアクセスが向上し、慢性疾患の有病率が上昇し、患者人口が多いため、ODT市場が急成長しています。インドや中国のような国では、高い人口密度と医療ニーズの高まりが大きな市場機会となっています。また、国内の製薬会社がODT製剤を開発する動向も高まっています。

口腔内崩壊錠市場-競合情勢：

口腔内崩壊錠（ODT）市場は競争が激しく、複数の主要企業が参入し、現在進行中の開発がその情勢を形成しています。市場各社は、味覚マスキングを改善し、崩壊時間を短縮した新しいODT製剤を開発しています。賦形剤技術や錠剤マトリックス設計の革新により、患者の全体的な使用感が向上しています。大手製薬企業は、アジア太平洋やラテンアメリカなどの新興市場におけるODT製品の拡大に注力しています。このような拡大は、ヘルスケアへのアクセスが拡大し、患者にやさしい薬への需要が高まっていることが背景にあります。

目次

第1章 口腔内崩壊錠市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 口腔内崩壊錠の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 口腔内崩壊錠産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 口腔内崩壊錠市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 口腔内崩壊錠市場情勢

  • 口腔内崩壊錠市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 口腔内崩壊錠市場- 薬剤タイプ別

  • 概要
    • セグメントシェア分析
    • 抗精神病薬
    • 抗てんかん薬
    • 降圧剤
    • 抗不安薬
    • 抗アレルギー薬
    • プロトンポンプ阻害剤
    • その他

第8章 口腔内崩壊錠市場- 適応症別

  • 概要
    • セグメントシェア分析
    • 神経疾患
    • 心血管疾患
    • 消化器疾患
    • アレルギー疾患
    • その他

第9章 口腔内崩壊錠市場- 流通チャネル別

  • 概要
    • セグメントシェア分析
    • 病院薬局
    • オンライン薬局
    • その他

第10章 口腔内崩壊錠市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- 口腔内崩壊錠業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Johnson &Johnson
    • Pfizer Inc.
    • Novartis AG
    • Roche Holding AG
    • GlaxoSmithKline（GSK）
    • Viatris Inc.
    • Aurobindo Pharma
    • Teva Pharmaceutical Industries Ltd.
    • Zydus Cadilla
    • Eli Lilly and Company
    • Sanofi
    • Boehringer Ingelheim
    • AbbVie Inc.
    • Amgen Inc.
    • Daiichi Sankyo
    • MigVax
    • Dr. Reddy's Laboratories
    • Others

第12章 アナリストの全方位展望

目次
Product Code: ANV3641

REPORT HIGHLIGHT

Orally Disintegrating Tablet Market size was valued at USD 13,123.12 Million in 2023, expanding at a CAGR of 8.1% from 2024 to 2032.

An Orally Disintegrating Tablet (ODT) is a type of medication that is designed to dissolve quickly in the mouth without needing water. This can be particularly useful for people who have difficulty swallowing traditional tablets or capsules, such as children or elderly patients.

Orally Disintegrating Tablet Market- Market Dynamics

Increasing improved bioavailability and convenience to use are expected to propel market demand

ODTs can enhance the bioavailability of certain drugs, making them more effective. This is particularly beneficial for medications that require rapid onset of action. ODTs are increasingly used in a variety of therapeutic areas beyond just pediatric and geriatric care, including mental health, allergies, and pain management. This broader application helps drive market growth. Patients often prefer ODTs over traditional tablets due to their ease of use and the reduced need for water. Increased patient compliance can lead to better therapeutic outcomes and, subsequently, higher demand.

Furthermore, ODTs offer a practical solution for patients who have difficulty swallowing traditional tablets or capsules. This includes children, elderly individuals, and those with certain medical conditions. The ease of administration without needing water contributes to higher patient compliance. Innovations in tablet formulation technologies have improved the taste, stability, and efficacy of ODTs. Advances in manufacturing processes allow for more effective and patient-friendly ODTs.

Orally Disintegrating Tablet Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.1% over the forecast period (2024-2032)

Based on Drug Type segmentation, the anti-allergic drugs segment was predicted to show maximum market share in the year 2023, owing to growing allergic disorders.

Based on Indication segmentation, the cardiovascular diseases segment was the leading Indication in 2023, owing to the high need for ODTs in cardiovascular therapies.

Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel segment in 2023, owing to the high demand for ODTs in hospitals.

Based on region, North America was the leading revenue generator in 2023, due to the growing prevalence of chronic diseases.

Orally Disintegrating Tablet Market- Segmentation Analysis:

The Global Orally Disintegrating Tablet Market is segmented based on Drug Type, Indication, Distribution Channel, and Region.

The market is divided into seven categories based on Drug Type: anti-psychotics, anti-epileptics, anti-hypertensives, anxiolytics, anti-allergic drugs, proton pump inhibitors, and others. The anti-allergic drugs segment dominates the market. The high prevalence of allergic diseases is growing the demand for anti-allergic tablets.

The market is divided into five categories based on Indication: neurological diseases, cardiovascular diseases, gastrointestinal diseases, allergic diseases, and others. The cardiovascular diseases segment dominates the market. ODTs are widely used for treating every cardiovascular disease which boosts segment growth.

The market is divided into three categories based on Distribution Channels: hospital pharmacies, online pharmacies, and others. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. The online pharmacies segment is estimated to grow at the fastest rate over the forecast period.

Orally Disintegrating Tablet Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a significant share of the global ODT market, largely due to its advanced healthcare infrastructure and high prevalence of chronic diseases. The Asia-Pacific region is experiencing rapid growth in the ODT market due to rising healthcare access, increasing chronic disease prevalence, and a large patient population. Significant market opportunities in countries like India and China, are driven by high population density and increasing healthcare needs. There is also a growing trend towards domestic pharmaceutical companies developing ODT formulations.

Orally Disintegrating Tablet Market- Competitive Landscape:

The Orally Disintegrating Tablet (ODT) market is highly competitive, with several key players and ongoing developments shaping its landscape. Market players are developing new ODT formulations with improved taste-masking and faster disintegration times. Innovations in excipient technologies and tablet matrix design are enhancing the overall patient experience. Major pharmaceutical companies are focusing on expanding their ODT product offerings in emerging markets such as Asia-Pacific and Latin America. This expansion is driven by growing healthcare access and increasing demand for patient-friendly medication.

Recent Developments:

In March 2023, Zydus Cadilla got FDA approval for manufacturing Olanzapine ODT for nervous system diseases.

In June 2022, Catalent and MigVax announced the utilization of Zydis Bio orally disintegrating tablet technology.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ORALLY DISINTEGRATING TABLET MARKET KEY PLAYERS

  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Roche Holding AG
  • GlaxoSmithKline (GSK)
  • Viatris Inc.
  • Aurobindo Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadilla
  • Eli Lilly and Company
  • Sanofi
  • Boehringer Ingelheim
  • AbbVie Inc.
  • Amgen Inc.
  • Daiichi Sankyo
  • MigVax
  • Dr Reddy's Laboratories
  • Others

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019-2032

  • Anti-psychotics
  • Anti-epileptics
  • Anti-hypertensives
  • Anxiolytics
  • Anti-allergic Drugs
  • Proton Pump Inhibitors
  • Others

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032

  • Neurological Diseases
  • Cardiovascular Diseases
  • Gastrointestinal Diseases
  • Allergic Diseases
  • Others

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019-2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Others

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Orally Disintegrating Tablet Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Orally Disintegrating Tablet Market Snippet by Drug Type
    • 2.1.2. Orally Disintegrating Tablet Market Snippet by Indication
    • 2.1.3. Orally Disintegrating Tablet Market Snippet by Distribution Channel
    • 2.1.4. Orally Disintegrating Tablet Market Snippet by Country
    • 2.1.5. Orally Disintegrating Tablet Market Snippet by Region
  • 2.2. Competitive Insights

3. Orally Disintegrating Tablet Key Market Trends

  • 3.1. Orally Disintegrating Tablet Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Orally Disintegrating Tablet Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Orally Disintegrating Tablet Market Opportunities
  • 3.4. Orally Disintegrating Tablet Market Future Trends

4. Orally Disintegrating Tablet Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Orally Disintegrating Tablet Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Orally Disintegrating Tablet Market Landscape

  • 6.1. Orally Disintegrating Tablet Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Orally Disintegrating Tablet Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Anti-psychotics
    • 7.1.3. Anti-epileptics
    • 7.1.4. Anti-hypertensives
    • 7.1.5. Anxiolytics
    • 7.1.6. Anti-allergic Drugs
    • 7.1.7. Proton Pump Inhibitors
    • 7.1.8. Others

8. Orally Disintegrating Tablet Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 8.1.2. Neurological Diseases
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Gastrointestinal Diseases
    • 8.1.5. Allergic Diseases
    • 8.1.6. Others

9. Orally Disintegrating Tablet Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Others

10. Orally Disintegrating Tablet Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Orally Disintegrating Tablet Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Orally Disintegrating Tablet Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Orally Disintegrating Tablet Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Orally Disintegrating Tablet Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Orally Disintegrating Tablet Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Orally Disintegrating Tablet Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Johnson & Johnson
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Novartis AG
    • 11.2.4. Roche Holding AG
    • 11.2.5. GlaxoSmithKline (GSK)
    • 11.2.6. Viatris Inc.
    • 11.2.7. Aurobindo Pharma
    • 11.2.8. Teva Pharmaceutical Industries Ltd.
    • 11.2.9. Zydus Cadilla
    • 11.2.10. Eli Lilly and Company
    • 11.2.11. Sanofi
    • 11.2.12. Boehringer Ingelheim
    • 11.2.13. AbbVie Inc.
    • 11.2.14. Amgen Inc.
    • 11.2.15. Daiichi Sankyo
    • 11.2.16. MigVax
    • 11.2.17. Dr. Reddy's Laboratories
    • 11.2.18. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us